Anthropic Launches Claude Science, Sending Drug Discovery Stocks Lower
The AI firm’s new research environment for scientists and a cheaper, safer model prompted a sharp sell-off in pharmaceutical technology shares, while the company also announced internal drug discovery programmes and a grant initiative.
Anthropic also announced a grant programme that will fund up to 50 research projects with as much as $30,000 each in technology credits, plus computing resources from partner Modal. Priority will go to biology and biomedical sciences. Applications close on 15 July 2026, with selected projects announced by the end of that month and work running from September to December. The initiative, alongside the commercial launch, marks an acceleration of the company’s push into life sciences, a sector where AI firms are racing to convert laboratory promise into clinical and market impact.
How the same story is told elsewhere.
2 editorial groups · 1 languages
Anthropic's AI platform for science is seen as a threat to local pharmaceutical companies, already vulnerable to big tech competition. The drop in drug developer stocks is interpreted as a symptom of the Global South's technological dependence. The narrative highlights risks to domestic innovation and the need for regulation.
The launch of Anthropic's AI platform is presented as a natural step forward in scientific innovation, with the market reacting quickly to new possibilities. The drop in drug developer stocks is described as a temporary correction driven by competition. A technical and descriptive tone prevails, without alarmism.
Broaden your view
Iran Begins Week-Long Khamenei Funeral as Successor Stays Out of Sight
11 languages · 44 outlets
From Economy & MarketsCar Sales Accelerate in Emerging Markets as Smartphone Demand Stalls
4 languages · 10 outlets
From Science & HealthFirst Bundibugyo Virus Test Listed as Congo Outbreak Passes 1,500 Cases
3 languages · 5 outlets